Ardian enters into exclusive negotiations for the acquisition of Unither, alongside management

Ardian, the independent private investment company, today announces that it has submitted a binding offer and has entered into exclusive negotiations with Equistone, leading a consortium including in particular the historic shareholders Parquest Capital and CM-CIC Investissement to acquire their majority stake in Unither, a world-leading Contract Development and Manufacturing Organization (CDMO) in single unit dosage forms. The management team, led by Eric Goupil, Group CEO, will reinvest significantly in the company.

Unither Pharmaceuticals has become a globally renowned company for the development and manufacturing of sterile unit-doses, non-sterile liquids, liquid sticks, and solid and semi-solid medications for the pharmaceutical and generic drug industry. The company operates six manufacturing sites and one R&D center in France, USA and Brazil.

The transaction will be put before the Unither Work Council and is subject to the signing of a definitive agreement, as well as the approval of the relevant competition and regulatory authorities.